ClinicalTrials.gg
CompletedNCT02556788Updated Nov 12, 2019Results posted

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

A Phase 3 interventional study of CD5789 (trifarotene) 50µg/g Cream and Placebo Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 81 sites in 8 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,212
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
Largest of 12
1,212 · median 507
Started
2015
with 2 others
Phase 3
6 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one has the largest enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 3rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Efficacy
  • Safety
  • Acne vulgaris
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is a male or female, 9 years of age or older, at Screening visit.
  • The Subject has moderate acne at Screening and Baseline.
  • The subject is a female of non
  • The subject is a female of childbearing potential with a negative pregnancy test and who is strictly abstinent or who agrees to use an effective and approved method for the duration of the study and at least 1 month after the last study drug application.

Exclusion criteria

Exclusion Criteria:

  • The subject has severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g.,chloracne, drug-induced acne, etc.).
  • The subject has any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part to the trial.
  • The subject has been exposed to excessive ultraviolet (UV) radiation within one month prior to the Baseline visit or the subject is planning intense UV exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.)
  • The subject is unwilling to refrain from use of prohibited medication during the clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,212 participants (actual)

Study arms

  • Experimental
    CD5789 (Trifarotene) 50µg/g Cream

    CD5789 (trifarotene) 50µg/g Cream

    Drug: CD5789 (trifarotene) 50µg/g Cream

  • Placebo comparator
    Placebo Cream

    Placebo Cream

    Drug: Placebo Cream

Interventions

  • DrugCD5789 (trifarotene) 50µg/g Cream

    Drug page: Trifarotene

    CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.

  • DrugPlacebo Cream

    Placebo cream applied once daily during 12 weeks.

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)

    Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

    Time frame: From Baseline to Week 12

07

Results

Posted Sep 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneCD5789 (Trifarotene) 50µg/g CreamPlacebo Cream
Started602610
Completed558573
Not completed4437

Outcome measures

PrimaryInvestigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)

Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

Time frame:
From Baseline to Week 12
Reported as:
Count of participants · Participants
Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
ParticipantsCD5789 (Trifarotene) 50µg/g CreamPlacebo Cream
Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)255157

Adverse events

Collected over Each participant's adverse events were collected starting at the first visit (screening) until the last visit (Week 12).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5789 (Trifarotene) 50µg/g Cream0/602 (0%)2/602 (0.3%)21/602 (3.5%)
Placebo Cream0/610 (0%)4/610 (0.7%)5/610 (0.8%)
Most frequent serious events
Most frequent serious events
EventCD5789 (Trifarotene) 50µg/g CreamPlacebo Cream
Ligament SprainInjury, poisoning and procedural complications1/6020/610
Suicide AttemptPsychiatric disorders1/6021/610
Major DepressionPsychiatric disorders1/6020/610
AsthmaRespiratory, thoracic and mediastinal disorders0/6021/610
AppendicitisInfections and infestations0/6021/610
SinusitisInfections and infestations0/6021/610
Most frequent other events
Showing 10 of 20
Most frequent other events
EventCD5789 (Trifarotene) 50µg/g CreamPlacebo Cream
Application Site IrritationGeneral disorders15/6020/610
Application Site PuritisGeneral disorders5/6022/610
Application Site PainGeneral disorders4/6020/610
Application Site DrynessGeneral disorders3/6020/610
SunburnInjury, poisoning and procedural complications2/6020/610
Skin IrritationSkin and subcutaneous tissue disorders2/6020/610
Drug Administered at Inappropriate SiteInjury, poisoning and procedural complications1/6020/610
LymphadenopathyBlood and lymphatic system disorders1/6020/610
Eyelid ExfoliationEye disorders1/6020/610
Eyelid EdemaEye disorders1/6020/610

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
<=18 years276294570
Between 18 and 65 years326316642
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
Female357338695
Male245272517
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
Hispanic or Latino6062122
Not Hispanic or Latino5425481090
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
American Indian or Alaska Native123
Asian268
Native Hawaiian or Other Pacific Islander011
Black or African American274269
White5655541119
More than one race224
Unknown or Not Reported538
Region of Enrollment
Region of Enrollment(Participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
Romania6465129
Hungary7466140
United States124154278
Czechia6360123
Ukraine7174145
Poland9296188
Russia10081181
Spain141428
Investigator Global Asssessment
Investigator Global Asssessment(participants)CD5789 (Trifarotene) 50µg/g CreamPlacebo CreamTotal
Clear000
Almost Clear000
Mild000
Moderate6026101212
Severe000
08

Study locations

81 sites
  • Galderma Investigational Site
    Birmingham, Alabama 35205, United States
  • Galderma Investigational Site
    Phoenix, Arizona 85032, United States
  • Galderma Investigational Site
    Tucson, Arizona 85712, United States
  • Galderma Investigational Site
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site
    Los Angeles, California 90036, United States
  • Galderma Investigational Site
    Murrieta, California 92562, United States
  • Galderma Investigational Site
    Santa Ana, California 92705, United States
  • Galderma Investigational Site
    Aventura, Florida 33180, United States
  • Galderma Investigational Site
    Miami Lakes, Florida 33016, United States
  • Galderma Investigational Site
    Miami, Florida 33144, United States
  • Galderma Investigational Site
    West Palm Beach, Florida 33406, United States
  • Galderma Investigational Site
    Corbin, Kentucky 40701, United States
  • Galderma Investigational Site
    Beverly, Massachusetts 01915, United States
  • Galderma Investigational Site
    Ann Arbor, Michigan 48103, United States
  • Galderma Investigational Site
    Detroit, Michigan 48202, United States
  • Galderma Investigational Site
    Brooklyn, New York 11203, United States
  • Galderma Investigational Site
    Stony Brook, New York 11790, United States
  • Galderma Investigational Site
    Wilmington, North Carolina 28401, United States
  • Galderma Investigational Site
    Fort Washington, Pennsylvania 19034, United States
  • Galderma Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Galderma Investigational Site
    Greer, South Carolina 29650, United States
  • Galderma Investigational Site
    Goodlettsville, Tennessee 37072, United States
  • Galderma Invetsigational site
    Austin, Texas 78759-8858, United States
  • Galderma Investigational Site
    Dallas, Texas 75230-5806, United States
  • Galderma Investigational Site
    Houston, Texas 77004, United States
  • Galderma Investigational Site
    Pflugerville, Texas 78660, United States
  • Galderma Investigational Site
    San Antonio, Texas 78249, United States
  • Galderma Investigational Site
    Webster, Texas 77598, United States
  • Galderma Investigational Site
    Walla Walla, Washington 99362, United States
  • Galderma Investigational Site
    Chomutov, 430 04, Czechia
  • Galderma Investigational Site
    Hradec Kralove, 500 05, Czechia
  • Galderma Investigational Site
    Kutna Hora, 284 01, Czechia
  • Galderma Investigational Site
    Olomouc, 775 20, Czechia
  • Galderma Investigational Site
    Pardubice, 532 03, Czechia
  • Galderma Investigational Site
    Praha 1, 11 000, Czechia
  • Galderma Investigational Site
    Praha 1, 110 00, Czechia
  • Galderma Investigational Site
    Praha, 190 11, Czechia
  • Galderma Investigational Site
    Budapest, 1035, Hungary
  • Galderma Investigational Site
    Budapest, 1089, Hungary
  • Galderma Investigational Site
    Debrecen, 4032, Hungary
  • Galderma Investigational Site
    Miskolc, 3529, Hungary
  • Galderma Investigational Site
    Pecs, 7632, Hungary
  • Galderma Investigational Site
    Szeged, 6720, Hungary
  • Galderma Investigational Site
    Szolnok, 5000, Hungary
  • Galderma Investigational Site
    Bialystok, 15-453, Poland
  • Galderma Investigational Site
    Gdansk, 80-152, Poland
  • Galderma Investigational Site
    Gdansk, 80-402, Poland
  • Galderma Investigational Site
    Gdansk, 80-546, Poland
  • Galderma Investigational Site
    Katowice, 40-036, Poland
  • Galderma investigational Site
    Katowice, 40-611, Poland
  • Galderma Investigational Site
    Katowice, 40-851, Poland
  • Galderma Investigational Site
    Lodz, 90-242, Poland
  • Galderma Investigational Site
    Sochaczew, 95-500, Poland
  • Galderma Investigational Site
    Warszawa, 01-817, Poland
  • Galderma investigational Site
    Warszawa, 02-657, Poland
  • Galderma Investigational Site
    Warszawa, 02-758, Poland
  • Galderma Investigational Site
    Wroclaw, 51-318, Poland
  • Galderma Investigational Site
    Wroclaw, 53-658, Poland
  • Galderma Investigational Site
    Brasov, 500283, Romania
  • Galderma Investigational Site
    Craiova, 200642, Romania
  • Galderma Investigational Site
    Iasi, 700381, Romania
  • Galderma Investigational Site
    Târgu-Mureş, 540530, Romania
  • Galderma Investigational Site
    Krasnodar, 3500 20, Russian Federation
  • Galderma Investigational Site
    Lipetsk, 398035, Russian Federation
  • Galderma Investigational Site
    Moscow, 107076, Russian Federation
  • Galderma Investigational Site
    Moscow, 119071, Russian Federation
  • Galderma Investigational Site
    Moscow, 121614, Russian Federation
  • Galderma Investigational Site
    Sr Petersburg, 194021, Russian Federation
  • Galderma Investigational Site
    St Petersburg, 194100, Russian Federation
  • Galderma Investigational Site
    Barcelona, 08206, Spain
  • Galderma Investigational Site
    Esplugues de Llobregat, 8950, Spain
  • Galderma Investigational site
    Madrid, 28009, Spain
  • Galderma Investigational Site
    Valencia, 46014, Spain
  • Galderma Investigational Site
    Dnipropetrovsk, 49044, Ukraine
  • Galderma Investigational Site
    Dnipropetrovsk, 49074, Ukraine
  • Galderma Investigational Site
    Ivano-Frankivsk, 76000, Ukraine
  • Galderma Investigational Site
    Kharkiv, 61057, Ukraine
  • Galderma Investigational Site
    Kyiv, 01601, Ukraine
  • Galderma Investigational Site
    Kyiv, 04209, Ukraine
  • Galderma Investigational Site
    Lviv, 79049, Ukraine
  • Galderma Investigational Site
    Uzhgorod, 88000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Feb 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 2 years 6 months after primary completion. A results delay was requested in May 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2015
First posted
Sep 22, 2015
Start
Nov 2015
Primary completionActual
Feb 7, 2017
CompletionActual
May 12, 2017
Results delay requested
May 16, 2018
Results first posted
Sep 3, 2019
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02556788
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 22, 2015
Start date
Nov 2015
Primary completion
Feb 7, 2017
Completion
May 12, 2017
Results posted
Sep 3, 2019
Last update
Nov 12, 2019

Study contacts

Kevin Chan
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion